Display options
Cite
Yajid AI, Zakariah MA, Mat Zin AA, et al. Potential Role of E4 Protein in Human Papillomavirus Screening: a Review. Asian Pac J Cancer Prev. 2017;18(2):315-319doi: 10.22034/APJCP.2017.18.2.315.
Yajid, A. I., Zakariah, M. A., Mat Zin, A. A., & Othman, N. H. (2017). Potential Role of E4 Protein in Human Papillomavirus Screening: a Review. Asian Pacific journal of cancer prevention : APJCP, 18(2), 315-319. https://doi.org/10.22034/APJCP.2017.18.2.315
Yajid, Aidy Irman, et al. "Potential Role of E4 Protein in Human Papillomavirus Screening: a Review." Asian Pacific journal of cancer prevention : APJCP vol. 18,2 (2017): 315-319. doi: https://doi.org/10.22034/APJCP.2017.18.2.315
Yajid AI, Zakariah MA, Mat Zin AA, Othman NH. Potential Role of E4 Protein in Human Papillomavirus Screening: a Review. Asian Pac J Cancer Prev. 2017 Feb 01;18(2):315-319. doi: 10.22034/APJCP.2017.18.2.315. PMID: 28345325; PMCID: PMC5454721.
Copy Download .nbib Format: NLM
Share it on

Asian Pac J Cancer Prev. 2017 Feb 01;18(2):315-319. doi: 10.22034/APJCP.2017.18.2.315.

Potential Role of E4 Protein in Human Papillomavirus Screening: a Review.

Asian Pacific journal of cancer prevention : APJCP

Aidy Irman Yajid, Mohd Azali Zakariah, Anani Aila Mat Zin, Nor Hayati Othman

Affiliations

  1. Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia. Email:[email protected]

PMID: 28345325 PMCID: PMC5454721 DOI: 10.22034/APJCP.2017.18.2.315

Abstract

In 2006, cervical cancer was reported as the second most common cancer in women of Malaysia. This type of cancer has been shown to correlate with persistent high risk human papillomavirus (HPV) infection. Although HPV is well known to induce cervical cancer, knowledge of pathways that link the latent stage of the viral replication cycle to precancerous and cancerous stages remains incomplete. However, it is interesting to note that the virus can be isolated from tissues ranging from normal to low-grade squamous intraepithelial lesions as well as high-grade intraepithelial lesions (HSILs), thus prompting scientists to develop HPV detection methods for screening. Detection of HPV using viral proteins such as L1 and E1 is proposed to be very useful in assisting the management of high risk infection and cervical cancer. These tests however can lead to false positive results, largely due to the exisstence of asymptomatic or transient HPV infections within any given individual. Somes observation indicate that use of HPV proteins such as E6 and E7 might lead to false positive results. However, one particular HPV protein, E4 shows potential as an accurate marker of the tissue state following HPV infection. E4 expression has been shown to correlate with the levels of HPV DNA incorporation by the host. Thus, it is possible that E4 could serve as a useful marker to define stages of viral carcinogenesis.

Creative Commons Attribution License

Keywords: HPV; E4; cervical cancer; screening

References

  1. Cell Cycle. 2006 Mar;5(6):567-8 - PubMed
  2. Mod Pathol. 2015 Jul;28(7):977-93 - PubMed
  3. J Virol. 2005 Apr;79(7):3998-4011 - PubMed
  4. Enferm Infecc Microbiol Clin. 2011 Jun-Jul;29(6):411-4 - PubMed
  5. J Virol. 1997 May;71(5):3554-62 - PubMed
  6. Mol Cell. 2006 Dec 28;24(6):867-76 - PubMed
  7. J Virol. 2001 Aug;75(15):7198-201 - PubMed
  8. Virology. 2010 May 10;400(2):233-9 - PubMed
  9. J Virol. 2004 Feb;78(4):2142-51 - PubMed
  10. J Virol. 2011 Oct;85(19):9984-97 - PubMed
  11. Clin Dermatol. 1985 Oct-Dec;3(4):43-55 - PubMed
  12. J Virol. 2003 Mar;77(5):2832-42 - PubMed
  13. Virus Genes. 2000;20(1):65-9 - PubMed
  14. Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):367-72 - PubMed
  15. Asian Pac J Cancer Prev. 2010;11(1):117-22 - PubMed
  16. J Clin Microbiol. 2011 Nov;49(11):3983-5 - PubMed
  17. PLoS One. 2012;7(12):e49974 - PubMed
  18. J Med Virol. 2010 Apr;82(4):605-15 - PubMed
  19. J Virol. 2009 Apr;83(8):3668-83 - PubMed
  20. J Pathol. 1999 Sep;189(1):12-9 - PubMed
  21. Oncogene. 1992 Jan;7(1):27-32 - PubMed
  22. J Invest Dermatol. 1993 Dec;101(6):843-51 - PubMed
  23. J Virol Methods. 2009 Mar;156(1-2):77-83 - PubMed
  24. Br J Cancer. 2003 May 19;88(10):1570-7 - PubMed
  25. J Med Virol. 2011 Aug;83(8):1358-61 - PubMed
  26. J Virol. 2002 Oct;76(19):9806-18 - PubMed
  27. J Clin Microbiol. 2009 Dec;47(12):3895-901 - PubMed
  28. Int J Cancer. 2007 Aug 1;121(3):621-32 - PubMed
  29. Virology. 2011 Jun 5;414(2):153-63 - PubMed
  30. Southeast Asian J Trop Med Public Health. 2011 Sep;42(5):1113-8 - PubMed
  31. PLoS Pathog. 2009 Feb;5(2):e1000318 - PubMed
  32. J Virol. 2009 Mar;83(5):2067-74 - PubMed
  33. J Med Virol. 2011 Aug;83(8):1377-82 - PubMed
  34. PLoS One. 2010 Sep 17;5(9):null - PubMed
  35. J Clin Virol. 2005 Mar;32 Suppl 1:S7-15 - PubMed
  36. Virology. 2013 Oct;445(1-2):80-98 - PubMed
  37. Nature. 1982 Oct 7;299(5883):529-34 - PubMed
  38. J Virol Methods. 2012 Mar;180(1-2):7-10 - PubMed
  39. Intervirology. 2004;47(1):48-56 - PubMed
  40. BMC Cancer. 2016 Nov 5;16(1):852 - PubMed
  41. EMBO J. 2012 May 22;31(14 ):3212-27 - PubMed
  42. J Virol. 2003 Jan;77(1):673-84 - PubMed
  43. J Virol. 2002 Oct;76(20):10401-16 - PubMed
  44. Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1157-64 - PubMed
  45. J Cell Sci. 2010 Aug 15;123(Pt 16):2810-22 - PubMed
  46. J Virol. 2006 Aug;80(15):7416-26 - PubMed
  47. Gynecol Oncol. 2006 Jan;100(1):95-100 - PubMed
  48. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 - PubMed
  49. Gynecol Oncol. 2010 Jun;118(1 Suppl):S12-7 - PubMed
  50. Lancet Infect Dis. 2007 Jul;7(7):453-9 - PubMed
  51. Cell Cycle. 2009 May 1;8(9):1319-23 - PubMed
  52. Gynecol Oncol. 2008 Aug;110(2):179-84 - PubMed
  53. Virology. 2006 Feb 5;345(1):290-8 - PubMed
  54. J Virol. 2011 Aug;85(16):8080-92 - PubMed
  55. J Virol. 2008 Aug;82(16):8196-203 - PubMed
  56. Adv Virus Res. 2008;72:155-205 - PubMed
  57. Virology. 1996 Apr 1;218(1):114-26 - PubMed

Publication Types